Skip to main content

Advertisement

Table 2 Summary characteristics of surveyed outpatient health facilities—Southern Malawi, 2015 (N = 105)

From: Health worker adherence to malaria treatment guidelines at outpatient health facilities in southern Malawi following implementation of universal access to diagnostic testing

  n %
Operation of health facility
 Ministry of Health 84 80.0
 CHAM 21 20.0
Health facility type
 Health centre 90 85.7
 Community hospital 9 8.6
 District hospital 6 5.7
Diagnostic capacity
 Microscopy service functional for full day of survey 26 24.8
 RDTs in stock for full day of survey 83 79.1
 Either microscopy or RDT functional for day of surveya 94 89.5
 Haemoglobin testing functional for full day 11 10.5
Infrastructure and equipment available on day of survey
 Clean drinking water 93 88.6
 Cups for administering oral medications available 69 65.7
 Functioning hanging or standing scale 98 90.5
 Functioning thermometer 69 65.7
Availability of 2013 malaria treatment guidelines on day of survey
 Copy of 2013 national or other reference material on malaria treatment guidelines 50 47.6
 Wall flowchart with 2013 malaria treatment guidelines 14 13.3
  1. aAn additional 4 facilities had testing availability for part of the day
Anti-malarial drugs in stock for the full day on day of survey
A. First-line treatment for uncomplicated malaria in pregnant women (1st trimester) and children <5 kg
 Quinine tablets 37 35.2
B. First-line treatment for uncomplicated malaria in all other patients
 At least one artemether-lumefantrine (AL) formulation 96 91.4
 AL 1 × 6 dose-pack (regular or dispersible) 88 83.8
 AL 2 × 6 dose-pack (regular or dispersible) 77 73.3
 AL 3 × 6 dose-pack 83 79.1
 AL 4 × 6 dose-pack 77 73.3
C. Second-line treatment for uncomplicated malaria (treatment failure or when AL is contra-indicated)
 Artesunate-amodiaquine (co-formulated or co-blistered) 32 30.5
 Any first- or second-line anti-malarial treatment for uncomplicated malaria 98 93.3
D. Pre-referral treatment for severe malaria
 Any injectable pre-referral treatment (artesunate or quinine) 103 98.1
 Parenteral artesunate 88 83.8
 Parenteral quinine 94 89.5
 Artesunate suppositories 6 5.7
  1. aAn additional 4 facilities had testing availability for part of the day